PregLem, HRA Pharma deal

HRA Pharma granted PregLem North American rights to develop and commercialize ulipristal acetate for benign gynecological disorders. PregLem already has rights under a 2007 deal to the selective progesterone receptor modulator (SPRM) in Europe, where the compound is known as Esmya and is in Phase III testing for uterine fibroids. PregLem will be responsible for completing development in North America. Financial details were not disclosed (see BioCentury, Dec. 10, 2007). ...